What You Should Know:
– Benchling, the leading life sciences cloud, today announced the launch of RNA Therapeutics R&D, a new digital solution that allows scientists to design, analyze, and develop complex RNA therapeutics in a unified cloud platform for the first time.
– More than 1,000 R&D organizations/customers can now accelerate collaboration, speed, and simplicity for RNA research via Benchling — an important advance for biotech.
Biopharmaceutical R&D teams can use Benchling to collaborate across biology and chemistry workflows to support their collective efforts on this hybrid modality. These teams can work faster and improve their overall success rate by unifying traditionally siloed tasks and phases in one cloud-based solution. For the first time, scientists can design chemically modified oligonucleotides with ease, centralize experimental context and results, standardize on syntax, and collaborate with teammates more effectively on a single platform.
Scientists using Benchling can now:
– Create complex oligonucleotides with ease and contextualized experimental insights: Benchling saves researchers from having to repeatedly create their RNA from the atomic-level up. The visualization capabilities with Benchling’s HELM editor are built for oligo-level editing with the ability to zoom in and out on specific areas for modification. Experimental data is contextualized within Benchling’s solution, making high-quality data actionable throughout the oligo design process.
– Standardize data and simplify collaboration to accelerate the entire RNA therapeutic lifecycle: Benchling’s monomer library helps researchers quickly search and customize the most common base monomers. The embedded HELM notation support standardizes complex biomolecule representation so multidisciplinary teams can all access, understand, and contribute to the molecule’s ongoing development. The robust, integrated platform easily registers or creates oligos with uniqueness checks to save time and prevent redundant work.
Why It Matters
RNA has become a household name thanks to the successful development of mRNA-powered COVID-19 vaccines, and the category is exploding with more than 1,300 drugs in the pipeline. RNA is extremely complex — and teams just haven’t had the right tools to manage those elaborate datasets across multiple, often large and complicated organizations. Benchling is taking aim at that paralyzing complexity with a cloud platform tailored to RNA — helping biopharmaceutical teams get to world-changing breakthroughs (like Moderna/Pfizer) faster.